EUVIMEDEUVIMED entdecken
Open Access

TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment

Mai M Abdelmageed, Eirini Kefaloyianni, Akshayakeerthi Arthanarisami, Yohei Komaru, Jeffrey J Atkinson, Andreas Herrlich iD

Nephrology Dialysis Transplantation · 04.05.2023 · 38 (5) · 1139-1150

DOI: 10.1093/ndt/gfac290 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 21.10.2022. Verfasst von Mai M Abdelmageed und 5 weiteren Autor:innen. Beteiligte Einrichtung: Washington University School of Medicine in Saint Louis, Department of Medicine, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Ureteral Obstruction, Renal Insufficiency, Chronic, Acute Kidney Injury, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammation is a key driver of the transition of acute kidney injury to progressive fibrosis and chronic kidney disease (AKI-to-CKD transition). Blocking a-disintegrin-and-metalloprotease-17 (ADAM17)-dependent ectodomain shedding, in particular of epidermal growth factor receptor (EGFR) ligands and of the type 1 inflammatory cytokine tumor necrosis factor (TNF), reduces pro-inflammatory and pro-fibrotic responses after ischemic AKI or unilateral ureteral obstruction (UUO), a classical fibrosis model. Metalloprotease or EGFR inhibition show significant undesirable side effects in humans. In retrospective studies anti-TNF biologics reduce the incidence and progression of CKD in humans. Whether TNF has a role in AKI-to-CKD transition and how TNF inhibition compares to EGFR inhibition is largely unknown.

Methods

Mice were subjected to bilateral renal ischemia-reperfusion injury or unilateral ureteral obstruction. Kidneys were analyzed by histology, immunohistochemistry, qPCR, western blot, mass cytometry, scRNA sequencing, and cytokine profiling.

Results

Here we show that TNF or EGFR inhibition reduce AKI-to-CKD transition and fibrosis equally by about 25%, while combination has no additional effect. EGFR inhibition reduced kidney TNF expression by about 50% largely by reducing accumulation of TNF expressing immune cells in the kidney early after AKI, while TNF inhibition did not affect EGFR activation or immune cell accumulation. Using scRNAseq data we show that TNF is predominantly expressed by immune cells in AKI but not in proximal tubule cells (PTC), and PTC-TNF knockout did not affect AKI-to-CKD transition in UUO. Thus, the anti-inflammatory and anti-fibrotic effects of the anti-TNF biologic etanercept in AKI-to-CKD transition rely on blocking TNF that is released from immune cells recruited or accumulating in response to PTC-EGFR signals.

Conclusion

Short-term anti-TNF biologics during or after AKI could be helpful in the prevention of AKI-to-CKD transition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ureteral ObstructionRenal Insufficiency, ChronicAcute Kidney InjuryBiological ProductsHumansMiceAnimalsEtanerceptRetrospective StudiesTumor Necrosis Factor InhibitorsKidneyErbB ReceptorsTumor Necrosis Factor-alphaFibrosis

Stichwörter der Autor:innen

TNFacute kidney injurychronic kidney diseaseepidermal growth factor receptorfibrosis

Substanzen

EtanerceptTumor Necrosis Factor InhibitorsErbB ReceptorsTumor Necrosis Factor-alphaBiological ProductsEGFR protein, human

Autor:innen und Institutionen

  • Washington University School of Medicine in Saint Louis, Department of Medicine, St. Louis, MO, USA.
  • Division of Nephrology.
  • Division of Pulmonary and Critical Care Medicine.

ORCID-Profile: Andreas Herrlich

Förderung

  • BLRD VA
  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • American Heart Association
  • American Society of Nephrology
  • Mochida Memorial Foundation
  • Uehara Memorial Foundation

Zitieren

APA

Abdelmageed, M. M., Kefaloyianni, E., Arthanarisami, A., Komaru, Y., Atkinson, J. J., & Herrlich, A. (2023). TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment. Nephrology Dialysis Transplantation, 38(5), 1139-1150. https://doi.org/10.1093/ndt/gfac290

Vancouver

Abdelmageed MM, Kefaloyianni E, Arthanarisami A, Komaru Y, Atkinson JJ, Herrlich A. TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment. Nephrology Dialysis Transplantation. 2023;38(5):1139-1150. doi:10.1093/ndt/gfac290

BibTeX
@article{Abdelmageed2023,
  author = {Abdelmageed, Mai M and Kefaloyianni, Eirini and Arthanarisami, Akshayakeerthi and Komaru, Yohei and Atkinson, Jeffrey J and Herrlich, Andreas},
  title = {TNF or EGFR inhibition equally block AKI-to-CKD transition: opportunities for etanercept treatment},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {5},
  pages = {1139--1150},
  doi = {10.1093/ndt/gfac290}
}
Kostenlos starten →